Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,699.38
(
1.01%
)
US TECH 100
23,954.00
(
-0.25%
)
Dow Jones
46,946.41
(
0.00%
)
Brent Oil
100.10
(
1.83%
)
Bitcoin
74,097.45
(
-1.00%
)
News Focus
News Focus
Post# of 257251
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: go seek post# 46647

Monday, 05/14/2007 2:46:57 PM

Monday, May 14, 2007 2:46:57 PM

Post# of 257251
Quiz answer:

>>
1. Generic polysaccharide drugs
2. Generic polypeptide drugs
3. Generic glycoprotein drugs
What is all this in reference to?
<<

This is the progression in MNTA’s business model from easiest to hardest.

Step #1 has already reached the ANDA submission stage for generic Lovenox.

Step #2 is under development with partner NVS to create a generic version of Copaxone. An ANDA will follow.

Step #3 is in early development using two undisclosed glycoproteins designated by NVS. The regulatory path is not yet established.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now